Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1 17Phase 3 10Phase NA 5Phase 1/2 5Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 3Lymphoid 3Plasma cell 2Classical hematology 2Sarcoma 1Other solid neoplasm 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Neuroblastoma 1

Interventions

Temozolomide 11Lomustine 6Radiotherapy 4Magnetic Resonance Spectroscopy 3Etoposide 3Carboplatin 3Bevacizumab 3vocimagene amiretrorepvec 2Vincristine 2Radiation 2Gefitinib 2veliparib 1trofosfamide 1trametinib 1tozuleristide 1tinostamustine 1regorafenib 1omburtamab I-131 1entrectinib 1dabrafenib 1cobimetinib 1carbon-11 acetate 1capmatinib 1antisecretory factor 1alectinib 1Vorinostat 1Vemurafenib 1Thiotepa 1Sunitinib 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Melphalan × CNS × Clear all
NCT00539500 2019-07-26

Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma

M.D. Anderson Cancer Center

Phase 2/3 Terminated
3 enrolled 4 charts
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡